- Home
- BCAB vs NRSN Comparison
BCAB vs NRSN Comparison
Compare BCAB & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAB
- NRSN
- Stock Information
- Founded
- BCAB 2007
- NRSN 2017
- Country
- BCAB United States
- NRSN Israel
- Employees
- BCAB N/A
- NRSN N/A
- Industry
- BCAB Medicinal Chemicals and Botanical Products
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- BCAB Health Care
- NRSN Health Care
- Exchange
- BCAB Nasdaq
- NRSN Nasdaq
- Market Cap
- BCAB 31.5M
- NRSN 26.0M
- IPO Year
- BCAB 2020
- NRSN 2021
- Fundamental
- Price
- BCAB $0.72
- NRSN $1.17
- Analyst Decision
- BCAB Hold
- NRSN Buy
- Analyst Count
- BCAB 3
- NRSN 2
- Target Price
- BCAB $1.00
- NRSN $14.00
- AVG Volume (30 Days)
- BCAB 1.1M
- NRSN 1.4M
- Earning Date
- BCAB 11-06-2025
- NRSN 09-17-2025
- Dividend Yield
- BCAB N/A
- NRSN N/A
- EPS Growth
- BCAB N/A
- NRSN N/A
- EPS
- BCAB N/A
- NRSN N/A
- Revenue
- BCAB $11,000,000.00
- NRSN N/A
- Revenue This Year
- BCAB N/A
- NRSN N/A
- Revenue Next Year
- BCAB N/A
- NRSN N/A
- P/E Ratio
- BCAB N/A
- NRSN N/A
- Revenue Growth
- BCAB N/A
- NRSN N/A
- 52 Week Low
- BCAB $0.24
- NRSN $0.80
- 52 Week High
- BCAB $2.53
- NRSN $2.60
- Technical
- Relative Strength Index (RSI)
- BCAB 56.79
- NRSN 45.81
- Support Level
- BCAB N/A
- NRSN $1.14
- Resistance Level
- BCAB $0.84
- NRSN $1.28
- Average True Range (ATR)
- BCAB 0.07
- NRSN 0.15
- MACD
- BCAB -0.00
- NRSN 0.03
- Stochastic Oscillator
- BCAB 85.96
- NRSN 21.36
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.